Since the French government launched its vaccination campaign against the coronavirus (COVID-19) on December 27, 2020, the number of vaccinated people in France steadily rose. As of January 1, 2023, 79 percent of the French population has received three vaccine doses against the coronavirus. With 83 percent of vaccinated people, the French region with the highest vaccination rate was Brittany. On the other hand, only 67 percent of people in Corsica were fully vaccinated (three doses) against the coronavirus.

Since France launched its vaccination campaign to fight the COVID-19 pandemic on December 27, 2020, around 70 percent of the French population received three doses of vaccine against the coronavirus. As of June 26, 2023, the share of unvaccinated people in France reached 14 percent. From an age group perspective, people aged 70 to 74 were the most fully vaccinated age group in France. On the other hand, 96.5 percent of children aged five to nine were not vaccinated against COVID-19.

In France, 53.8 million people have received the two doses required for complete vaccination against COVID-19 as of July 2023. France launched its vaccination campaign against the coronavirus epidemic (COVID-19) on December 27, 2020. Since then, the number of people who received at least one dose of vaccine amounted to some 54.7 million, according to the French national health agency figures. In addition, 41 million people received a booster shot (a third vaccine dose) in France. The recent evolution of COVID-19 in France As of December 2023, France's cumulative number of COVID-19 infections reached 39 million. France registered over 20,000 cases of COVID-19 within a week (between April 26 and May 3). As of December 2023, France's COVID-19 death toll stood at 168,000 deaths. The hospital situation in France As of May 2022, the country registered around 12,700 hospital patients due to COVID-19. At the same time, just over 700 ICU patients were in French intensive care units due to the coronavirus. According to the geographical distribution of patients, Parisian ICUs treated the highest number of patients.

The number of COVID-19 vaccination doses administered in France rose to 154451978 as of Oct 27 2023. This dataset includes a chart with historical data for France Coronavirus Vaccination Total.

In France, the number of mandatory vaccines increased from ***** to ****** for children born from January 2018. These vaccines are for Diphtheria, Tetanus, Poliomyelitis, Pertussis, Hemophilus B, Hepatitis B, Meningitis, Pneumococcus, Mumps, Measles, and Rubella. As of 2018, over ** percent of children aged 24 months received a DTP vaccination (Diphteria, Tetanus, and Pertussis), whereas the meningococcal C immunization stood at **** percent. Nonetheless, certain immunizations can differ on an individual basis due to medical circumstances.

Forecast: Measles Vaccination Rates Among Children in France 2022 - 2026 Discover more data with ReportLinker!

Forecast: Diphtheria, Tetanus and Pertussis Vaccination Rates Among Children in France 2022 - 2026 Discover more data with ReportLinker!

Immunization, measles (% of children ages 12-23 months) in France was reported at 95 % in 2023, according to the World Bank collection of development indicators, compiled from officially recognized sources. France - Immunization, measles (% of children ages 12-23 months) - actual values, historical data, forecasts and projections were sourced from the World Bank on July of 2025.

As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

شاهد أكثر من 20 مليون مؤشر اقتصادي لـ 196 دولة. احصل على مؤشرات مجانية، وبيانات تاريخية، ورسوم بيانية، وأخبار، وتوقعات لـ 196 دولة.

France: Percent of children ages 12-23 months with measles immunization: The latest value from 2022 is 94 percent, unchanged from 94 percent in 2021. In comparison, the world average is 84 percent, based on data from 187 countries. Historically, the average for France from 1983 to 2022 is 78 percent. The minimum value, 15 percent, was reached in 1983 while the maximum of 94 percent was recorded in 2020.

Forecast: Total Influenza Vaccination Rates in France 2022 - 2026 Discover more data with ReportLinker!

France FR: Immunization: HepB3: % of One-Year-Old Children data was reported at 90.000 % in 2017. This stayed constant from the previous number of 90.000 % for 2016. France FR: Immunization: HepB3: % of One-Year-Old Children data is updated yearly, averaging 44.500 % from Dec 1998 (Median) to 2017, with 20 observations. The data reached an all-time high of 90.000 % in 2017 and a record low of 24.000 % in 1999. France FR: Immunization: HepB3: % of One-Year-Old Children data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank.WDI: Health Statistics. Child immunization rate, hepatitis B is the percentage of children ages 12-23 months who received hepatitis B vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized after three doses.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

France FR: Immunization: DPT: % of Children Aged 12-23 Months data was reported at 96.000 % in 2017. This stayed constant from the previous number of 96.000 % for 2016. France FR: Immunization: DPT: % of Children Aged 12-23 Months data is updated yearly, averaging 97.000 % from Dec 1990 (Median) to 2017, with 28 observations. The data reached an all-time high of 99.000 % in 2013 and a record low of 94.000 % in 1993. France FR: Immunization: DPT: % of Children Aged 12-23 Months data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s France – Table FR.World Bank: Health Statistics. Child immunization, DPT, measures the percentage of children ages 12-23 months who received DPT vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against diphtheria, pertussis (or whooping cough), and tetanus (DPT) after receiving three doses of vaccine.; ; WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/).; Weighted average;

An evaluation was conducted to predict the economic and clinical burden of vaccinating all immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines versus BNT162b2 variant-adapted vaccines in Fall 2023 and Spring 2024 in France. The number of symptomatic SARS-CoV-2 infections, hospitalizations or deaths due to COVID-19, and long COVID cases, costs and quality-adjusted life years (QALYs) were estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from the original and BA.4/5 variant-adapted vaccines, suggesting higher protection against infection and hospitalization with mRNA-1273 vaccines. VE estimates were combined with COVID-19 incidence and probability of COVID-19 severe outcomes. Uncertainty surrounding VE, vaccine coverage, infection incidence, hospitalization and mortality rates, costs and QALYs were evaluated in sensitivity analyses. In an ideal situation where 100% coverage is achieved, the mRNA-1273 variant-adapted vaccine is predicted to prevent an additional 3,882 infections, 357 hospitalizations, 81 deaths, and 326 long COVID cases when compared to BNT162b2 variant-adapted vaccines in 230,000 IC individuals. This translates to €10.1 million cost-savings from a societal perspective and 645 QALYs gained. Results were consistent across all analyses and most sensitive to variations surrounding VE and coverage. These findings highlight the importance of increasing vaccine coverage, and ability to induce higher levels of protection with mRNA-1273 formulations in this vulnerable population.

In France, hexavalent vaccine are mandatory for children and must be administered from the age of 2 months. They protect against * diseases: diphtheria, tetanus, pertussis, polio, hepatitis B and Haemophilus influenzae type B infections. The vast majority of children born in France in 2020 were thus immunized against these diseases with a hexavalent vaccine. This 6-in-1 vaccine has both an individual and collective protection objective (Herd immunity).

Since 2018, the hexavalent vaccination coverage (with at least one dose at 8 months) increased from **** to **** percent among children. Furthermore, roughly ** percent of the cohort of children born in 2020 received at least three doses (at 21 months).

Disclaimer

All information presented here is for display purpose only, and may not be complete nor accurate. This information does not constitute a financial advice, and should not be used to make any investment decisions or financial transactions. This author rejects any claims for liabilities resulting from the use, misuse, or abuse of this information. Use at your own risk.

Context

This small dataset has been created in order to prove my mom it's important for the world to get as much people as we can vaccinated

Content

You will find a dataset made of 2 taken from the french website https://www.data.gouv.fr gathering a lot of datasets

Features

This document gathers both the vaccine data day by day and cumulated, and the COVID-19 best indicators to follow the evolution of the sanitary crisis.

Here are the features :

• extract_date : row date formatted dd/mm/yyyy

• tx_incid : The incidence rate corresponds to the number of people who tested positive (RT-PCR and antigen test) for the first time in more than 60 days compared to the size of the population. It is expressed per 100,000 inhabitants and makes it possible to compare geographic areas with one another.

• R : The virus reproduction number: this is the average number of people an infected person can infect. If the effective R is greater than 1, the epidemic develops; if it is less than 1, the epidemic recedes. This indicator, stopped on Tuesday and updated on Thursday, is an indicator of the epidemiological situation approximately 7 days previously and must be interpreted in the light of screening and data reporting activities. The indicator is updated once a week.

• taux occupation sae (%) : This indicator reflects the level of demand for resuscitation but also the level of stress on hospital resuscitation capacities. This is the proportion of patients with COVID-19 currently in intensive care, intensive care, or in a continuous monitoring unit compared to the total beds in initial capacity, that is to say before increasing the capacity. resuscitation beds in a hospital.

• tx_pos : The positivity rate corresponds to the number of people tested positive (RT-PCR and antigen test) for the first time in more than 60 days compared to the total number of people tested positive or negative over a given period; and who have never tested positive in the previous 60 days.

• n_dose1 : Number of 1rst dose of vaccine administered this day

• n_complet : Number of complete coverage granted this day (1 dose for J&J - 2 doses for Pfitzer/AstraZenecca/Moderna - 1 dose if you ever had COVID-19 before)

• n cum dose1 : Cumulated number of 1rst doses administered

• n cum complet : Cumulated number of complete coverages

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in va

Since January 1, 2018, pneumococcal vaccines are mandatory for infants born in France. The vast majority of children born in France in 2020 were thus immunized against the bacterium Streptococcus pneumoniae responsible for cases of pneumonia, meningitis, and sepsis. Since 2018, the pneumococcal vaccination coverage (with at least one dose at 8 months) increased from 99.4 to 99.7 percent among infants. Furthermore, roughly 91 percent of the cohort of children born in 2020 received at least three doses (at 21 months).

1For this age group, the figure was obtained from Ref. [36].